IL272245A - Methods for treating active eosinophilic esophagitis - Google Patents

Methods for treating active eosinophilic esophagitis

Info

Publication number
IL272245A
IL272245A IL272245A IL27224520A IL272245A IL 272245 A IL272245 A IL 272245A IL 272245 A IL272245 A IL 272245A IL 27224520 A IL27224520 A IL 27224520A IL 272245 A IL272245 A IL 272245A
Authority
IL
Israel
Prior art keywords
methods
eosinophilic esophagitis
treating active
active eosinophilic
treating
Prior art date
Application number
IL272245A
Other languages
English (en)
Hebrew (he)
Other versions
IL272245B1 (en
Inventor
Allen Radin
Jennifer D Hamilton
Leda Mannent
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Allen Radin
Jennifer D Hamilton
Leda Mannent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology, Allen Radin, Jennifer D Hamilton, Leda Mannent filed Critical Regeneron Pharma
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/fr
Publication of IL272245A publication Critical patent/IL272245A/en
Publication of IL272245B1 publication Critical patent/IL272245B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL272245A 2017-08-04 2018-08-03 Methods for treating active eosinophilic esophagitis IL272245B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US201762561593P 2017-09-21 2017-09-21
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (fr) 2017-08-04 2018-08-03 Méthodes de traitement de l'oesophagite à éosinophiles active

Publications (2)

Publication Number Publication Date
IL272245A true IL272245A (en) 2020-03-31
IL272245B1 IL272245B1 (en) 2024-10-01

Family

ID=63113646

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272245A IL272245B1 (en) 2017-08-04 2018-08-03 Methods for treating active eosinophilic esophagitis

Country Status (8)

Country Link
EP (1) EP3661551A1 (fr)
JP (2) JP7417515B2 (fr)
CN (1) CN111032084A (fr)
AU (1) AU2018311981A1 (fr)
CA (1) CA3071528A1 (fr)
IL (1) IL272245B1 (fr)
MA (1) MA49744A (fr)
MX (1) MX2020001305A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208104A1 (fr) * 2022-04-29 2023-11-02 中山康方生物医药有限公司 Anticorps anti-ra de l'il-4 humaine et son application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CA2924873A1 (fr) * 2013-10-23 2015-04-30 Genentech, Inc. Methodes de diagnostic et de traitement de troubles eosinophiliques
TW201643179A (zh) * 2015-03-11 2016-12-16 葛蘭素史克智慧財產發展有限公司 Ｔｓｌｐ結合蛋白

Also Published As

Publication number Publication date
MX2020001305A (es) 2020-03-09
JP7417515B2 (ja) 2024-01-18
JP2020529434A (ja) 2020-10-08
AU2018311981A1 (en) 2020-02-20
CN111032084A (zh) 2020-04-17
IL272245B1 (en) 2024-10-01
CA3071528A1 (fr) 2019-02-07
RU2020109331A (ru) 2021-09-06
KR20200035442A (ko) 2020-04-03
RU2020109331A3 (fr) 2021-12-28
EP3661551A1 (fr) 2020-06-10
JP2024016237A (ja) 2024-02-06
MA49744A (fr) 2020-06-10

Similar Documents

Publication Publication Date Title
EP3500264A4 (fr) Méthode de traitement de l'oesophagite éosinophile
IL285201A (en) EZH2 inhibitors for the treatment of lymphoma
IL256056A (en) ezh2 inhibitors for the treatment of lymphoma
EP3500289A4 (fr) Procédés de traitement de la trachéobronchomalacie
GB201417487D0 (en) Method for treating an animal substrate
HK1244217A1 (zh) 用於治療蛋白質病的方法
IL278247B (en) mct4 inhibitors to treat the disease
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
HK1251965A1 (zh) 用於治療癲癇的方法
GB2567616B (en) Treatment method
GB2571601B (en) Treatment method
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
IL252904A0 (en) Methods and factors for treating diseases
SG11202001806TA (en) Treatment method
GB2566005B (en) Method for stabilizing soil
IL270867A (en) Treatment method
IL266605A (en) Methods for treating bone and cartilage damage are common
IL272245A (en) Methods for treating active eosinophilic esophagitis
SG11202003127WA (en) Methods for treating lymphomas
EP3148307B8 (fr) Procede de traitement de semences
IL275091A (en) Methods for treating Gaucher's disease
IL271967A (en) Methods for treating congenital hypersecretion of insulin
IL281343A (en) Methods for treating pancreatitis
EP3310361A4 (fr) Méthode de traitement ou de prévention de la sécheresse oculaire